Secondary Progressive Multiple Sclerosis: Definition and Measurement

CNS Drugs

Volumn 30, Issue 6, 2016, Pages 517-526

  Plantone, Domenico ^a   De Angelis, Floriana ^a   Doshi, Anisha ^a   Chataway, Jeremy ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

BRAIN ATROPHY; BRIEF VISUOSPATIAL MEMORY TEST; CALIFORNIA VERBAL LEARNING TEST; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC IMAGING; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; INFLAMMATION; LABORATORY TEST; MAGNETIZATION TRANSFER RATIO; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; MULTIPLE SCLEROSIS QUALITY OF LIFE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PACED AUDITORY SERIAL ADDITION TEST; PATHOGENESIS; PATIENT REPORTED INDICES FOR MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; REVIEW; SPINAL CORD ATROPHY; STUDY DESIGN; SYMBOL DIGIT MODALITIES TEST; RECURRENT DISEASE; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84966713047     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0340-9     Document Type: Review

References (152)

1. Charcot J-M. Leçons sur les Maladies du Système Nerveux. Paris A. Delahaye. 1885;26.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.
3. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129:595–605.
4. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903–12.
5. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs. 2005;19:369–76.
6. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129:584–94.
7. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1039–43.
8. Sand IK, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 2014;20(12):1654–7.
9. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci. 2003;206:135–7.
10. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.
11. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73:1616–23.
12. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–8.
13. McAlpine D. Multiple Sclerosis. Br Med J. 1957;1:475–80.
14. Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, de Groot V, Reuling IEW, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology. 2004;63:335–9.
15. Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:15–9.
16. Confavreux C. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606–16.
17. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci. 2000;21:S831–8.
18. Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler. 2001;7:59–65.
19. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003;9:260–74.
20. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis results of an international survey. Neurology. 1996;46:907–11.
21. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, Mcdowell F, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–68.
22. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–31.
23. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992;55:671–6.
24. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurol. 2006;5:343–54.
25. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14:208–23.
26. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210–8.
27. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol. 2006;65:855–65.
28. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705–12.
29. Frisullo G, Plantone D, Marti A, Iorio R, Damato V, Nociti V, et al. Type 1 immune response in progressive multiple sclerosis. J Neuroimmunol. 2012;249:112–6.
30. Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol. 1999;45:247–50.
31. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol. 2004;146:209–15.
32. Christensen JR, Börnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-Helper, Th17- and activated B-cells and correlates with progression. PLoS One. 2013;8:e57820.
33. Plantone D, Marti A, Frisullo G, Iorio R, Damato V, Nociti V, et al. Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. J Neuroimmunol. 2013;265:124–7.
34. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134:2755–71.
35. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 2011;122:155–70.
36. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2006;130:1089–104.
37. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164–74.
38. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134:534–41.
39. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477–93.
40. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175–89.
41. Calabrese M, Filippi M, Gallo P. Cortical lesions in multiple sclerosis. Nat Rev Neurol. 2010;6:438–44.
42. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated epstein-barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899–912.
43. Su KG, Banker G, Bourdette D, Forte M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep. 2009;9:411–7.
44. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA. 2004;101:8168–73.
45. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006;59:478–89.
46. Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci. 1992;12:430–9.
47. D’haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011;10:657–66.
48. Motl RW, McAuley E, Snook EM. Physical activity and multiple sclerosis: a meta-analysis. Mult Scler. 2005;11:459–63.
49. Russo C, Morabito F, Luise F, Piromalli A, Battaglia L, Vinci A, et al. Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis. J Neurol. 2008;255:64–9.
50. Sahin S, Aksungar FB, Topkaya AE, Yildiz Z, Boru UT, Ayalp S, et al. Increased plasma homocysteine levels in multiple sclerosis. Mult Scler. 2007;13:945–6.
51. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology. 2010;35:267–74.
52. Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology. 2008;30:234–8.
53. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996;6:259–74.
54. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17.
55. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Brück W, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol. 2003;62:25–33.
56. Alexander JS, Zivadinov R, Maghzi A-H, Ganta VC, Harris MK, Minagar A. Multiple sclerosis and cerebral endothelial dysfunction: mechanisms. Pathophysiology. 2011;18:3–12.
57. Koudriavtseva T. Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. Front Neurol. 2014;5:119.
58. Koudriavtseva T, Renna R, Plantone D, Mainero C. Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors. Front Neurol. 2015;6:63.
59. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383:2213–21.
60. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363:1607–8.
61. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003;17:905–7.
62. van der Most PJ, Dolga AM, Nijholt IM, Luiten PGM, Eisel ULM. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88:64–75.
63. Schmeer C, Kretz A, Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci. 2006;24:79–95.
64. EMA. Guideline on clinical investigation of MPs for the treatment of multiple sclerosis (EMA/CHMP/771815/2011), Rev. 2. Guideline. 2015;44:20.
65. Khan O. Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology. 2007;68(S64–71):S91–6.
66. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5:256–66.
67. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology. 2009;72:705–11.
68. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis trials. Mult Scler. 1995;1:37–47.
69. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.
70. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5:244–50.
71. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–82.
72. Hobart J, Freeman J. Thompson a. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain. 2000;123:1027–40.
73. Amato MP, Ponziani G. Quantification of impairment in MS: discussion of the scales in use. Mult Scler. 1999;5:216–9.
74. Cohen JA, Reingold SC, Polman CH, Wolinsky JS. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012;11:467–76.
75. Cohen JA, Fischer JS, Bolibrush DM, Jak AJ, Kniker JE, Mertz LA, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology. 2000;54:802–6.
76. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988;38:1793–8.
77. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. Ann Neurol. 1997;42:379–82.
78. Rudick R, Cutter G, Reingold S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler. 2002;8:359–65.
79. Miller DM, Rudick RA, Cutter G, Baier M, Fisher JS. Clinical significance of the multiple sclerosis functional composite. Arch Neurol. 2000;57:1319–24.
80. Kalkers NF, Bergers L, de Groot V, Lazeron RH, van Walderveen MA, Uitdehaag BM, et al. Concurrent validity of the MS Functional composite using MRI as a biological disease marker. Neurology. 2001;56:215–9.
81. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler. 2000;6:373–7.
82. Kragt JJ, van der Linden FAH, Nielsen JM, Uitdehaag BMJ, Polman CH. Clinical impact of 20 % worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler. 2006;12:594–8.
83. Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler. 2009;15:984–97.
84. Brochet B, Deloire MSA, Bonnet M, Salort-Campana E, Ouallet JC, Petry KG, et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler. 2008;14:1242–9.
85. Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, et al. Contrast letter acuity as a visual component for the multiple sclerosis functional composite. Neurology. 2003;61:1367–73.
86. Benedict RHB, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12:549–58.
87. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685–91.
88. Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol. 2016;23:282–9.
89. Strober L, Englert J, Munschauer F, Weinstock-Guttman B, Rao S, Benedict RHB. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief repeatable neuropsychological battery and the minimal assessment of cognitive function in MS. Mult Scler. 2009;15:1077–84.
90. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RHB. Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult Scler. 2007;13:52–7.
91. Pardini M, Uccelli A, Grafman J, Yaldizli O, Mancardi G, Roccatagliata L. Isolated cognitive relapses in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2014;85:1035–7.
92. Delis DC, Kramer JH, Kaplan E, Ober BA. California verbal learning test—second edition. Adult Version. Manual. Test. 2000.
93. Benedict RHB. Revision of the brief visuospatial memory test—revised. Psychol Assess 1997;145–53.
94. Langdon D, Amato M, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler J. 2012;18:891–8.
95. Benedict RH, Walton MK. Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change? Mult Scler J. 2012;18:1673–9.
96. Doward LC, Mckenna SP, Meads DM, Twiss J, Eckert BJ. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). 2015;1092–102.
97. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4:187–206.
98. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996;47(1):129–39.
99. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124:962–73.
100. Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, et al. Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol. 2012;259:237–45.
101. Simon JH. Brain atrophy in multiple sclerosis: what we know and would like to know. Mult Scler. 2006;12:679–87.
102. Pelletier D, Garrison K, Henry R. Measurement of whole-brain atrophy in multiple sclerosis. J. neuroimaging. 2004;14:11S–9S.
103. de Bresser J, Portegies MP, Leemans A, Biessels GJ, Kappelle LJ, Viergever MA. A comparison of MR based segmentation methods for measuring brain atrophy progression. Neuroimage. 2011;54:760–8.
104. Vrenken H, Jenkinson M, Horsfield MA, Battaglini M, Van Schijndel RA, Rostrup E, et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol. 2013;260:2458–71.
105. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007;68:634–42.
106. Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004;127:1101–7.
107. Chard DT, Griffin CM, Parker GJM, Kapoor R. Thompson a J, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:327–37.
108. Sastre-Garriga J, Ingle GT, Chard DT, Cercignani M, Ramió-Torrentà L, Miller DH, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain. 2005;128:1454–60.
109. Fisher E, Lee J-C, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64:255–65.
110. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008;64:247–54.
111. Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler. 2014;20:72–80.
112. De Stefano N, Arnold DL. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult Scler J. 2015;675–7.
113. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, Horga A, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler. 2013;19:1175–81.
114. Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage. 2000;11:805–21.
115. Fischl B. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11–22.
116. Nakamura K, Guizard N, Fonov VS, Narayanan S, Collins DL, Arnold DL. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. NeuroImage Clin. 2014;4:10–7.
117. Nakamura K, Fox R, Fisher E. CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage. 2011;54:278–89.
118. van Walderveen MAA, Kamphorst W, Scheltens P, van Waesberghe JHTM, Ravid R, Valk J, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology. 1998;50:1282–8.
119. Mallik S, Samson RS, Wheeler-Kingshott CAM, Miller DH. Imaging outcomes for trials of remyelination in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:1396–404.
120. Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002;8:532–3.
121. Kearney H, Miller DH, Ciccarelli O. Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value. Nat Rev Neurol. 2015;11:327–38.
122. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry. 2003;74:1090–4.
123. Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009;15:1195–205.
124. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60:44–51.
125. Horsfield MA, Sala S, Neema M, Absinta M, Bakshi A, Sormani P, et al. Rapid semi automatic segmentation of spinal cord from Magnetic Resonance Images: application in multiple sclerosis. Neuroimage. 2011;50:446–55.
126. Rovira A, Alonso J. 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. Neuroimaging Clin N Am. 2013;23:459–74.
127. Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx. 2005;2:197–214.
128. De Stefano N, Filippi M, Miller D, Pouwels PJ, Rovira A, Gass A, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology. 2007;69:1942–52.
129. Vavasour IM, Laule C, Li DKB, Traboulsee AL, MacKay AL. Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging. 2011;33:713–8.
130. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56:407–15.
131. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G. Diffusion tensor MR imaging of the human brain. Radiology. 1996;201:637–48.
132. Sbardella E, Tona F, Petsas N, Pantano P. DTI measurements in multiple sclerosis: evaluation of brain damage and clinical implications. Mult Scler Int. 2013;2013:671730.
133. Petracca M, Fleysher L, Oesingmann N, Inglese M. Sodium MRI of multiple sclerosis. NMR Biomed. 2016;29:153–61.
134. Zaaraoui W, Konstandin S, Audoin B, Nagel AM, Rico A, Malikova I, et al. Distribution of brain sodium accumulation correlates with disability in multiple sclerosis: a cross-sectional 23Na MR imaging study. Radiology. 2012;264:859–67.
135. Inglese M, Madelin G, Oesingmann N, Babb JS, Wu W, Stoeckel B, et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain. 2010;133:847–57.
136. Paling D, Solanky BS, Riemer F, Tozer DJ, Wheeler-Kingshott CAM, Kapoor R, et al. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Brain. 2013;136:2305–17.
137. Greenberg BM, Frohman E. Optical coherence tomography as a potential readout in clinical trials. Ther Adv Neurol Disord. 2010;3:153–60.
138. Lamirel C, Newman N, Biousse V. The use of optical coherence tomography in neurology. Rev Neurol Dis. 2009;6:E105–20.
139. Abalo-Lojo JM, Limeres CC, Gómez MA, Baleato-González S, Cadarso-Suárez C, Capeáns-Tomé C, et al. Retinal nerve fiber layer thickness, brain atrophy, and disability in multiple sclerosis patients. J Neuroophthalmol. 2014;34:23–8.
140. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69:1603–9.
141. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, García-Layana A, Bejarano B, Villoslada P. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology. 2007;68:1488–94.
142. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004;127:1463–78.
143. Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003;61:1720–5.
144. Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013;19:1597–603.
145. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64:402–4.
146. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler J. 2012;18:552–6.
147. Madeddu R, Farace C, Tolu P, Solinas G, Asara Y, Sotgiu MA, et al. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol. Sci. 2013;34:181–6.
148. Katsavos S, Anagnostouli M. Biomarkers in multiple sclerosis: an up-to-date overview. Mult Scler Int. 2013;2013:340508.
149. Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler. 2011;17:81–8.
150. Koch MW, Cutter G, Stys PK, Yong VW, Metz LM. Treatment trials in progressive MS—current challenges and future directions. Nat Rev Neurol. 2013;9:496–503.
151. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.
152. Montalban X, Hemmer B, Rammohan K, Giovannoni G, De Seze J, Bar-Or A, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: results of the Phase III double-blind, placebo-controlled ORATORIO study. Neurology. 2016;86(Supp.16):S49.001.